Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ianalumab - MorphoSys/Novartis

Next Previous
Drug Profile

Ianalumab - MorphoSys/Novartis

Alternative Names: NOV-5; NVP-VAY736; VAY-736

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antirheumatics; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B-cell activation factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura; Lupus nephritis; Sjogren's syndrome; Systemic lupus erythematosus
  • Phase II/III Autoimmune hepatitis
  • Phase II Hidradenitis suppurativa; Rheumatoid arthritis; Systemic scleroderma
  • Phase I Non-Hodgkin's lymphoma
  • Discontinued Chronic lymphocytic leukaemia; Idiopathic pulmonary fibrosis; Multiple sclerosis; Pemphigus vulgaris

Most Recent Events

  • 26 Jun 2025 Novartis Pharmaceuticals plans a phase II VAY RE-HIT trial for Idiopathic thrombocytopenic purpura and Autoimmune haemolytic anaemia (Treatment-experienced) (IV) in August 2025 (NCT07039422)
  • 24 Feb 2025 Novartis Pharmaceuticals terminates a phase I trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in Italy, Australia, China, Germany, Japan, South Korea, Singapore (Parenteral) due to the business decision and not due to any safety or tolerability concerns (NCT04903197)
  • 24 Feb 2025 Novartis Pharmaceuticals terminates a phase I trial in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in Italy, Australia, China, Germany, Japan, South Korea, Singapore (Parenteral) due to the business decision and not due to any safety or tolerability concerns (NCT04903197)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top